Not applicableStudy completedNCT05680675What this trial is testingDual-Tracer Theranostic PETWho this might be right forNeuroendocrine TumorsProstate Cancer University of Utah 50
Large-scale testing (Phase 3)Active Not RecruitingNCT05459844What this trial is testingA Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETsWho this might be right forNeuroendocrine Tumors Sinotau Pharmaceutical Group 196
Testing effectiveness (Phase 2)WithdrawnNCT04915144What this trial is testing177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETsWho this might be right forNeuroendocrine TumorsCarcinoid TumorPulmonary Carcinoid Tumor+4 more British Columbia Cancer Agency
Large-scale testing (Phase 3)Active Not RecruitingNCT03049189What this trial is testingEfficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET PatientsWho this might be right forNeuroendocrine Tumors ITM Solucin GmbH 324
Early research (Phase 1)Study completedNCT00006368What this trial is testingYttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerWho this might be right forBrain and Central Nervous System TumorsBreast CancerGastrointestinal Carcinoid Tumor+5 more Novartis Pharmaceuticals 60
Testing effectiveness (Phase 2)Temporarily pausedNCT01876771What this trial is testingA Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine TumoursWho this might be right forCarcinoma, Neuroendocrine AHS Cancer Control Alberta 413
Testing effectiveness (Phase 2)Looking for participantsNCT04665739What this trial is testingTesting Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine TumorsWho this might be right forAdvanced Lung Neuroendocrine TumorFunctioning Lung Neuroendocrine TumorLocally Advanced Lung Neuroendocrine Neoplasm+9 more National Cancer Institute (NCI) 70
Post-approval studies (Phase 4)Looking for participantsNCT04081701What this trial is testing68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.Who this might be right forCNS TumorsMeningiomaEsthesioneuroblastoma+4 more Weill Medical College of Cornell University 200
Early research (Phase 1)Looking for participantsNCT05687123What this trial is testingTesting the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine TumorsWho this might be right forMetastatic Pancreatic Neuroendocrine TumorPancreatic NeoplasmStage III Pancreatic Neuroendocrine Tumor AJCC v8+2 more National Cancer Institute (NCI) 24
Not applicableActive Not RecruitingNCT03691064What this trial is testingPost-Authorization Long-Term Safety Study of LUTATHERAWho this might be right forNeuroendocrine Tumors Advanced Accelerator Applications 1,014
Testing effectiveness (Phase 2)UnknownNCT02236910What this trial is testingAn Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive TumoursWho this might be right forNeuroendocrine Carcinoma London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 66
Testing effectiveness (Phase 2)Looking for participantsNCT06045260What this trial is testing"Receptor Radionuclide Therapy With 177Lu-DOTATOCWho this might be right forNeuroendocrine TumorsParagangliomaPheochromocytoma Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 100
Early research (Phase 1)Active Not RecruitingNCT04609592What this trial is testingStudy of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive SurgeryWho this might be right forGastroenteropancreatic Neuroendocrine Tumor Stanford University 10